Taysha 유전자 치료, Inc.
US ˙ NasdaqGS ˙ US8776191061

SecurityTSHA / Taysha Gene Therapies, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership16,858,644 shares
Ownership 6.70%
Morgan Stanley ownership in TSHA / Taysha Gene Therapies, Inc.

2025-08-06 - Morgan Stanley has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 16,858,644 shares of Taysha Gene Therapies, Inc. (US:TSHA). This represents 6.7 percent ownership of the company. In their previous filing dated 2025-02-05 , Morgan Stanley had reported owning 17,629,264 shares, indicating a decrease of -4.37 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-08-06 2025-08-06 13G/A 17,629,264 16,858,644 -4.37 6.70 -22.09
2025-02-05 2025-02-05 13G 17,629,264 8.60

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TAYSHA GENE THERAPIES COM SHS 877619106 17,965,371 -113,147 -0.63 80,305 -19.24 0.0048
2026-05-27 2025-12-31 13F/A-1 TAYSHA GENE THERAPIES COM SHS 877619106 18,078,518 -1,229,085 -6.37 99,432 57.49 0.0059
2026-02-13 2025-12-31 13F TAYSHA GENE THERAPIES COM SHS 877619106 18,078,518 -1,229,085 99,432 0.0059
2026-05-27 2025-09-30 13F/A-1 TAYSHA GENE THERAPIES COM SHS 877619106 19,307,603 2,442,521 14.48 63,136 62.06 0.0038
2025-11-14 2025-09-30 13F TAYSHA GENE THERAPIES COM SHS 877619106 19,307,603 2,442,521 63,136 0.0038
2025-08-15 2025-06-30 13F TAYSHA GENE THERAPIES COM SHS 877619106 16,865,082 18,708 0.11 38,958 66.37 0.0025
2025-05-15 2025-03-31 13F TAYSHA GENE THERAPIES COM SHS 877619106 16,846,374 -793,992 -4.50 23,416 -23.27 0.0017
2025-05-15 2024-12-31 13F/A-1 TAYSHA GENE THERAPIES COM SHS 877619106 17,640,366 9,976,373 130.17 30,518 98.11 0.0021
2025-02-14 2024-12-31 13F TAYSHA GENE THERAPIES COM SHS 877619106 17,640,366 9,976,373 30,518 0.0021
2025-05-14 2024-09-30 13F/A-2 TAYSHA GENE THERAPIES COM SHS 877619106 7,663,993 186,596 2.50 15,405 -8.03 0.0011
2025-02-14 2024-09-30 13F/A-1 TAYSHA GENE THERAPIES COM SHS 877619106 7,663,993 186,596 15,405 0.0011
2024-11-14 2024-09-30 13F TAYSHA GENE THERAPIES COM SHS 877619106 7,663,993 186,596 15,405 0.0011
2025-05-14 2024-06-30 13F/A-2 TAYSHA GENE THERAPIES COM SHS 877619106 7,477,397 2,308,507 44.66 16,749 12.91 0.0013
2024-10-17 2024-06-30 13F/A-1 TAYSHA GENE THERAPIES COM SHS 877619106 7,477,397 2,308,507 16,749 0.0013
2024-08-14 2024-06-30 13F TAYSHA GENE THERAPIES COM SHS 877619106 7,477,397 2,308,507 16,749 0.0013
2024-10-17 2024-03-31 13F/A-2 TAYSHA GENE THERAPIES COM SHS 877619106 5,168,890 4,952,352 2,287.06 14,835 3,773.11 0.0012
2024-08-16 2024-03-31 13F/A-1 TAYSHA GENE THERAPIES COM SHS 877619106 5,168,890 4,952,352 14,835 0.0012
2024-05-15 2024-03-31 13F TAYSHA GENE THERAPIES COM SHS 877619106 5,168,890 4,952,352 14,835 0.0012
2024-08-16 2023-12-31 13F/A-1 TAYSHA GENE THERAPIES COM SHS 877619106 216,538 44,469 25.84 383 -29.47 0.0000
2024-02-13 2023-12-31 13F TAYSHA GENE THERAPIES COM SHS 877619106 216,538 44,469 383 0.0000
2023-11-15 2023-09-30 13F TAYSHA GENE THERAPIES COM SHS 877619106 172,069 40,761 31.04 544 531.40 0.0001
2023-08-14 2023-06-30 13F TAYSHA GENE THERAPIES COM SHS 877619106 131,308 43,495 49.53 87 22.86 0.0000
2023-05-15 2023-03-31 13F TAYSHA GENE THERAPIES COM SHS 877619106 87,813 64,206 271.98 70 32.08 0.0000
2023-02-14 2022-12-31 13F TAYSHA GENE THERAPIES COM SHS 877619106 23,607 -1,355 -5.43 53 10.42 0.0000
2022-11-14 2022-09-30 13F TAYSHA GENE THERAPIES COM SHS 877619106 24,962 -46,689 -65.16 48 -81.89 0.0000
2022-10-27 2022-06-30 13F/A-1 TAYSHA GENE THERAPIES COM SHS 877619106 71,651 -104,104 -59.23 265 -76.92 0.0000
2022-08-15 2022-06-30 13F TAYSHA GENE THERAPIES COM SHS 877619106 71,651 -104,104 265 0.0000
2022-10-27 2022-03-31 13F/A-1 TAYSHA GENE THERAPIES COM SHS 877619106 175,755 33,410 23.47 1,148 -30.76 0.0002
2022-05-13 2022-03-31 13F TAYSHA GENE THERAPIES COM SHS 877619106 175,755 33,410 1,148 0.0002
2022-02-14 2021-12-31 13F TAYSHA GENE THERAPIES COM SHS 877619106 142,345 17,251 13.79 1,658 -28.78 0.0002
2021-11-15 2021-09-30 13F TAYSHA GENE THERAPIES COM SHS 877619106 125,094 88,984 246.42 2,328 203.92 0.0003
2021-08-23 2021-06-30 13F/A-1 TAYSHA GENE THERAPIES COM SHS 877619106 36,110 13,149 57.27 766 64.38 0.0001
2021-08-16 2021-06-30 13F TAYSHA GENE THERAPIES COM SHS 877619106 36,110 13,149 766 0.0000
2021-05-17 2021-03-31 13F TAYSHA GENE THERAPIES COM SHS 877619106 22,961 -8,377 -26.73 466 -43.99 0.0001
2021-02-16 2020-12-31 13F TAYSHA GENE THERAPIES COM SHS 877619106 31,338 31,338 832 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.